Skip to main content

Table 2 SPIRIT figure

From: Community-based type 2 diabetes care by lay village health workers in rural Lesotho: protocol for a cluster-randomized trial within the ComBaCaL cohort study (ComBaCaL T2D TwiC)

Time point

 − 100–0

Cohort baseline

0

TwiC baseline

150–240

6-month follow-up

300–420

12-month follow-up

ComBaCaL cohort activities

 ComBaCaL cohort informed consenta

X

   

 Date of birth

X

   

 Height, weight, abdominal circumference

X

 

X

X

 Short medical historyb

X

   

 CVDRFsc

X

 

X

X

 T2D Screeningd

X

   

TwiC assessments

 FBG

 

X

X

X

 HbA1c

 

X

X

X

 Diabetes distresse

  

X

X

 Health beliefsf

 

X

 

X

 Quality of lifeg

 

X

X

X

 Self-reported access to care and to medication

 

X

X

X

 Blood lipid statush

 

X

X

X

 Current antidiabetic and lipid-lowering medication

X

X

X

X

 Adherence to antidiabetic medication

 

X

X

X

 Screening for relevant clinical events

 

X

X

X

 Screening for clinical alarm signs/symptoms

 

X

X

X

TwiC control

 Referral to health facility if required

 

X

X

X

TwiC intervention

 Offer metformini

 

X

X

X

 Offer lipid-lowering treatmenti

 

X

X

X

 Provide lifestyle counselling

 

X

X

X

 Provide treatment supportj

 

X

X

X

 Referral to health facilityk

 

X

X

X

  1. CVDRF cardiovascular disease risk factor, T2D type 2 diabetes, FBG fasting blood glucose, TwiC trial within cohort, LDL low-density lipoprotein, HDL high-density lipoprotein
  2. aIncluding consent to participation in TwiCs
  3. bIncluding personal and family history for T2D
  4. cPhysical activity using IPAQ-SF [34], dietary habits [35], and tobacco and alcohol use
  5. dAccording to Lesotho Standard Treatment Guidelines [31]
  6. eUsing the 5-item Problem Areas in Diabetes (PAID-5) scale [37, 38]
  7. fUsing the Beliefs about Medicines Questionnaire [39, 40]
  8. gUsing the EQ-5D-5L instrument [36]
  9. hTotal cholesterol, LDL, HDL, and triglycerides
  10. iTo participants eligible according to Lesotho Standard Treatment Guidelines [31]
  11. jTo participants receiving treatment from health facility (i.e. participants using insulin or more than one oral antidiabetic drug)
  12. kIn case of insufficient blood sugar control or clinical alarm symptoms